Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cg Pharmaceuticals Inc. is active in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is being handled by 1 distinct examiner, LAU, JONATHAN S. The presence of only 1 pending office action indicates that the company's current prosecution activity is concentrated on a single application. This allows for a focused approach to the specific examination requirements of 1 individual.
The pending matter is located within 1 distinct art unit. This suggests that the technical subject matter of the 1 pending office action is categorized within a specific niche of the Biotechnology & Pharmaceuticals field. The individual identified as the busiest examiner for the portfolio is the only examiner currently assigned to a pending case. This person is responsible for 1 pending office action.
Because the total number of pending office actions is 1, LAU, JONATHAN S manages the company's entire current pending workload. Practitioners should focus their strategy on the specific feedback provided by this 1 distinct examiner. The alignment of 1 distinct art unit and 1 distinct examiner represents a highly centralized prosecution path for the company at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAU, JONATHAN S | 1 | 63.9% | -17.2% |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839393 | USES OF IVALTINOSTAT FOR TREATING PANCREATIC CANCER | LAU, JONATHAN S | 1623 | §102§103DP | Non-Final OA | — | Pending | Aug 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCg Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jonathan S Lau has the most, with 1 of Cg Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
